David Solomon
American television director and film producer
3
APPEARANCES
3
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Jun 29, 2026
Thalia Therapeutics goes clinical-stage overnight with Sanmirna acquisition
0:06
0:15
0:21
0:30
0:51
2:06

Stephen GunnionHOST
For investors who don't know Thalia yet, can you give us a quick introduction to the company and what's driven this latest acquisition?

David SolomonGUEST
So Thalia is a name listed company that until not long ago was called N4 Pharma.

David SolomonGUEST
And together with the board, we effected a transformation to call it Thalia, which is the Greek word to grow or to blossom and to focus on RNA therapeutics.

David SolomonGUEST
We laid down in early 26 a proprietary cardiovascular gene silencing medicine, an SIRNA, and announced yesterday was the acquisition of Sanmirna, a privately held Delaware C Corporation that has an exclusive license to Mirastin, a medicine being developed at City of Hope.

David SolomonGUEST
And so with the acquisition now, Thalia brings the Sanmirna values and Sanmirna assets to Thalia.

Stephen GunnionHOST
David, what makes Mariston's approach different from existing treatments and how far along is the phase one trial? So this
THALIA THERAPEUTICS PLC - Investor Presentation
1:11
1:16
1:29
1:35
S
1:09speaker_1MODERATOR
Good afternoon, sir.

David SolomonGUEST
Thank you so much for the introduction and thank you all for your attendance today.

David SolomonGUEST
I'm the relatively new CEO of Thalia Therapeutics, and I'm delighted to be here today to tell you about our innovative RNA therapeutics programs.

David SolomonGUEST
So Thalia, as you might know in Greek means to flourish or to bloom or to blossom.

David SolomonGUEST
And really at Thalia, we are building now a new therapeutics, RNA therapeutics leader and champion.
39 MINS LATER
M
40:27MarianneMODERATOR
Looking ahead, at what stage would Thalia look to out-license or partner assets
Episode 182 - David Solomon - CEO of Thalia Therapeutics
8:56
9:10
9:16
9:24
T
8:46TomHOST
Um, just talk us through, like, what makes your approach different, um, compared to some of the other key players that are out there in the field.

David SolomonGUEST
So, you know, there are already, uh, there are already siRNA gene silencing medicines in the, in, in, in, uh, exploratory, uh, clinical trial mode against Lp(a) and against PCSK9.

David SolomonGUEST
In fact, there's one for PCSK9, uh, uh, uh, that is already commercial in Glycerin with Alnylam.

David SolomonGUEST
But the point of Lp(a) is Lp(a) is a target inside, uh, the body that is, uh, determined at birth.

David SolomonGUEST
And it s- it, it, it turns out that if you have high Lp(a) levels, you can diet and exercise, you can become a marathon runner, and Lp(a) levels will not go down.
10 MINS LATER
T
19:33TomHOST
But yeah, three people you'd like to sit down and, and have dinner with.